Please assess the completion status of the following clinical trial:

Trial Title: A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* macular edema associated with diabetes~* visual acuity between 20/50 and 20/200~Exclusion Criteria:~* recent laser therapy in the eye~* recent signs of uncontrolled diabetes~* blood pressure worse than 160/100~* severe cardiac disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sham Control (Type: SHAM_COMPARATOR): None
- Macugen (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).